Patents by Inventor Matthew Oliver Fraser

Matthew Oliver Fraser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110294881
    Abstract: A method is provided for using ?2? subunit calcium channel modulators or other compounds that interact with the ?2? calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, ?2? subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, ?3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
    Type: Application
    Filed: August 9, 2011
    Publication date: December 1, 2011
    Applicant: EDUSA PHARMACEUTICALS, INC.
    Inventors: Matthew Oliver Fraser, Karl Bruce Thor, Edward C. Burgard, Lee R. Brettman, Steven B. Landau, Daniel J. Ricca
  • Patent number: 7459430
    Abstract: The invention relates to methods of using Cav2.2 subunit calcium channel modulators to treat painful and non-painful lower urinary tract disorders and the related genitourinary tract disorders vulvodynia and vulvar vestibulitis in normal and spinal cord injured patients.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: December 2, 2008
    Assignee: Dynogen Pharmaceuticals, Inc.
    Inventors: Matthew Oliver Fraser, Karl Bruce Thor, Edward C. Burgard
  • Publication number: 20080275080
    Abstract: A method is provided for using ?2? subunit calcium channel modulators or other compounds that interact with the ?2? calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, ?2? subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, ?3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
    Type: Application
    Filed: April 11, 2008
    Publication date: November 6, 2008
    Applicant: Dynogen Pharmacueticals, Inc.
    Inventors: Matthew Oliver Fraser, Karl Bruce Thor, Edward C. Burgard, Lee R. Brettman, Steven B. Landau, Daniel J. Ricca
  • Patent number: 7223754
    Abstract: The invention relates to methods of using Cav2.2 subunit calcium channel modulators, particularly thiazolidinone, oxazolidinone, and imidazolone derivatives, to treat lower urinary tract and related disorders.
    Type: Grant
    Filed: November 17, 2004
    Date of Patent: May 29, 2007
    Assignee: Dynogen Pharmaceuticals, Inc.
    Inventors: Matthew Oliver Fraser, Karl Bruce Thor, Edward C. Burgard
  • Patent number: 7125848
    Abstract: A method is provided for using Cav2.2 subunit calcium channel modulators to treat non-inflammatory gastrointestinal tract disorders.
    Type: Grant
    Filed: June 10, 2004
    Date of Patent: October 24, 2006
    Assignee: Dynogen Pharmaceuticals, Inc.
    Inventors: Matthew Oliver Fraser, Steven B. Landau, Edward C. Burgard
  • Patent number: 7084116
    Abstract: The invention relates to methods of using Cav2.2 subunit calcium channel modulators to treat painful and non-painful lower urinary tract disorders and the related genitourinary tract disorders vulvodynia and vulvar vestibulitis in normal and spinal cord injured patients.
    Type: Grant
    Filed: March 10, 2004
    Date of Patent: August 1, 2006
    Assignee: Dynogen Pharmaceuticals, Inc.
    Inventors: Matthew Oliver Fraser, Karl Bruce Thor, Edward C. Burgard
  • Patent number: 7041704
    Abstract: The invention relates to methods of using sodium channel modulators, particularly TTX-R sodium channel modulators and/or activity dependent sodium channel modulators to treat a gastrointestinal tract disorders, particularly inflammatory bowel disorders and irritable bowel syndrome.
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: May 9, 2006
    Assignee: Dynogen Pharmaceuticals, Inc.
    Inventors: Edward C. Burgard, Steven B. Landau, Matthew Oliver Fraser
  • Publication number: 20040213842
    Abstract: The invention relates to methods of using sodium channel modulators, particularly TTX-R sodium channel modulators and/or activity dependent sodium channel modulators to treat gastrointestinal tract disorders, particularly inflammatory bowel disorders and irritable bowel syndrome.
    Type: Application
    Filed: January 30, 2004
    Publication date: October 28, 2004
    Applicant: Dynogen Pharmaceuticals, Inc.
    Inventors: Edward C. Burgard, Steven B. Landau, Matthew Oliver Fraser
  • Publication number: 20040209960
    Abstract: The invention relates to methods of using sodium channel modulators, particularly TTX-R sodium channel modulators and/or activity dependent sodium channel modulators to treat painful and non-painful lower urinary tract disorders, particularly painful and non-painful overactive bladder with and/or without loss of urine.
    Type: Application
    Filed: January 30, 2004
    Publication date: October 21, 2004
    Applicant: Dynogen Pharmaceuticals, Inc.
    Inventors: Edward C. Burgard, Karl Bruce Thor, Matthew Oliver Fraser
  • Publication number: 20040198822
    Abstract: A method is provided for using &agr;2&dgr; subunit calcium channel modulators or other compounds that interact with the &agr;2&dgr; calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, &agr;2&dgr; subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, &bgr;3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
    Type: Application
    Filed: March 22, 2004
    Publication date: October 7, 2004
    Applicant: Dynogen Pharmacueticals, Inc.
    Inventors: Matthew Oliver Fraser, Karl Bruce Thor, Edward C. Burgard, Lee R. Brettman, Steven B. Landau, Daniel J. Ricca
  • Publication number: 20040198775
    Abstract: The invention relates to methods of using Cav2.2 subunit calcium channel modulators to treat painful and non-painfull lower urinary tract disorders and the related genitourinary tract disorders vulvodynia and vulvar vestibulitis in normal and spinal cord injured patients.
    Type: Application
    Filed: March 10, 2004
    Publication date: October 7, 2004
    Applicant: Dynogen Pharmaceuticals, Inc.
    Inventors: Matthew Oliver Fraser, Karl Bruce Thor, Edward C. Burgard
  • Publication number: 20040142034
    Abstract: A method is provided for treatment of non-painful bladder disorders, particularly non-painful overactive bladder without loss of urine. The method comprises administration of an &agr;2&dgr; subunit calcium channel modulator, including gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, amino acid compounds, and other compounds that interact with the &agr;2&dgr; calcium channel subunit.
    Type: Application
    Filed: December 19, 2003
    Publication date: July 22, 2004
    Applicant: Dynogen Pharmaceuticals, Inc.
    Inventors: Karl Bruce Thor, Edward C. Burgard, Matthew Oliver Fraser